Announcement on Wholly-Owned Subsidiary Obtaining Approval for Marketing Application of Aminolevulinic Acid Hydrochloride API

Guangdong Zhongsheng Pharmaceutical Co.,Ltd.·May 11, 2026

✨ AI Summary

Zhongsheng Pharma announces its wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical, has received approval from China's NMPA for its Aminolevulinic Acid Hydrochloride API marketing application. This approval signifies compliance with national standards and allows domestic use and sales, enriching the company's API pipeline and supporting R&D and sales expansion. The company anticipates positive impacts on future performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Announcement on Wholly-Owned Subsidiary Obtaining Approval for Marketing Application of Aminolevulinic Acid Hydrochloride API

The company and the board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.

Guangdong Zhongsheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company")'s wholly-owned subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., recently received the "Approval Letter for Marketing Application of Chemical Raw Material Drug" for Aminolevulinic Acid Hydrochloride issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Main Content of the "Approval Letter for Marketing Application of Chemical Raw Material Drug"

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.